Matthew A. Gubens, M.D., M.S.
Dr. Matthew A. Gubens is a thoracic oncologist at the UCSF Thoracic Surgery and Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center. He specializes in treating patients diagnosed with non-small cell lung cancer, small cell lung cancer, thymoma and thymic carcinoma, and malignant pleural mesothelioma. Dr. Gubens is actively involved in research seeking new treatment strategies for these challenging diseases, with a particular focus on the use of immunotherapy.[1]
Education and Career
Dr. Gubens completed his undergraduate degree at Yale University, where he earned a B.A. in Ethics, Politics, and Economics. He earned an M.S. in Health Policy and Management at Harvard School of Public Health and earned his M.D. at Stanford University School of Medicine. Following his early medical education, he completed a residency in Internal Medicine at the University of California, San Francisco, and a fellowship in Medical Oncology at Stanford University.
Since then, Dr. Gubens has practiced as a thoracic medical oncologist at UCSF. He is the Medical Director of Thoracic Medical Oncology, an Associate Professor of Medicine, and serves as Vice Chair of the UCSF Cancer Center Protocol Review and Monitoring Committee.
He is the lung cancer liaison to the UCSF Cancer Immunotherapy Program; Chair-Elect of the ASCO Evidence-Based Medicine Committee which oversees the ASCO Guidelines program; and co-chair of the ASCO Thoracic Guideline Advisory Group. He also serves on the National Comprehensive Cancer Network panels for non-small cell lung cancer, mesothelioma, and thymic malignancies.[1]
Research Interests and Memberships
Dr. Gubens’ research interest centers on the role of immunotherapy in the treatment of malignant mesothelioma and lung cancer. He is active in several clinical trials studying new compounds and treatment strategies, working to translate laboratory-based findings to the clinic.
Dr. Gubens is a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Thymic Malignancy Interest Group, and the American College of Physicians.
Dr. Gubens combines attentive treatment of patients with innovative research to deliver better outcomes and quality of life for patients with malignant mesothelioma and lung cancers.
